

I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claim 27 without prejudice to renewal.

Please enter the amendment to claim 26, as shown below.

1.-25. (Canceled)

26. (Currently amended) A method of treating nasal polyps, comprising administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist to a patient suffering from nasal polyps, wherein said EGF-R antagonist is a kinase inhibitor selective for EGF-R.

27. (Canceled)

28. (Previously presented) The method of claim 26, wherein the antagonist is administered by injection.

29. (Previously presented) The method of claim 28, wherein the antagonist is administered intravenously with a carrier in the form of normal saline solution.

30. (Previously presented) The method of claim 26, wherein the antagonist is administered by liposome delivery.

31. (Previously presented) The method of claim 30, wherein said liposome is sterically stabilized and administered intravenously.

32. (Previously presented) The method of claim 26, wherein the antagonist is administered by inhalation.

33. (Previously presented) The method of claim 32, wherein the antagonist is in a dry powder formulation.

34. (Previously presented) The method of claim 26, wherein the antagonist is administered by oral delivery.

35. (Previously presented) The method of claim 26, wherein the antagonist is in an aqueous or ethanolic solution.

36. (Previously presented) The method of claim 26, wherein the patient is a human.